<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35594156</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>145</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Mild motor impairment as prodromal state in amyotrophic lateral sclerosis: a new diagnostic entity.</ArticleTitle><Pagination><StartPage>3500</StartPage><EndPage>3508</EndPage><MedlinePgn>3500-3508</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awac185</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis, when viewed as a biological entity rather than a clinical syndrome, probably evolves along a continuum, with the initial clinically silent phase eventually evolving into clinically manifest amyotrophic lateral sclerosis. Since motor neuron degeneration is incremental and cumulative over time, it stands to reason that the clinical syndrome of amyotrophic lateral sclerosis is probably preceded by a prodromal state characterized by minor motor abnormalities that are initially insufficient to permit a diagnosis of amyotrophic lateral sclerosis. This prodromal period, however, is usually missed, given the invariably long delays between symptom onset and diagnostic evaluation. The Pre-Symptomatic Familial ALS Study, a cohort study of pre-symptomatic gene mutation carriers, offers a unique opportunity to observe what is typically unseen. Here we describe the clinical characterization of 20 pre-symptomatic mutation carriers (in SOD1, FUS and C9orf72) whose phenoconversion to clinically manifest disease has been prospectively studied. In so doing, we observed a prodromal phase of mild motor impairment in 11 of 20 phenoconverters. Among the n = 12 SOD1 A4V mutation carriers, phenoconversion was characterized by abrupt onset of weakness, with a short (1-3.5 months) prodromal period observable in a small minority (n = 3); the observable prodrome invariably involved the lower motor neuron axis. By contrast, in all n = 3 SOD1 I113T mutation carriers, diffuse lower motor neuron and upper motor neuron signs evolved insidiously during a prodromal period that extended over a period of many years; prodromal manifestations eventually coalesced into a clinical syndrome that is recognizable as amyotrophic lateral sclerosis. Similarly, in all n = 3 C9orf72 hexanucleotide repeat expansion mutation carriers, focal or multifocal manifestations of disease evolved gradually over a prodromal period of 1-2 years. Clinically manifest ALS also emerged following a prodromal period of mild motor impairment, lasting &gt;4 years and &#x223c;9 months, respectively, in n = 2 with other gene mutations (SOD1 L106V and FUS c.521del6). On the basis of this empirical evidence, we conclude that mild motor impairment is an observable state that precedes clinically manifest disease in three of the most common genetic forms of amyotrophic lateral sclerosis (SOD1, FUS, C9orf72), and perhaps in all genetic amyotrophic lateral sclerosis; we also propose that this might be true of non-genetic amyotrophic lateral sclerosis. As a diagnostic label, mild motor impairment provides the language to describe the indeterminate (and sometimes intermediate) transition between the unaffected state and clinically manifest amyotrophic lateral sclerosis. Recognizing mild motor impairment as a distinct clinical entity should generate fresh urgency for developing biomarkers reflecting the earliest events in the degenerative cascade, with potential to reduce the diagnostic delay and to permit earlier therapeutic intervention.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benatar</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4241-5135</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Granit</LastName><ForeName>Volkan</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-6519-7225</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0003-0094-5429</Identifier><AffiliationInfo><Affiliation>Department of Clinical Science, Neurosciences, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grignon</LastName><ForeName>Anne-Laure</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McHutchison</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0103-8580</Identifier><AffiliationInfo><Affiliation>Department of Psychology, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Center for MND Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cosentino</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malaspina</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wuu</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS105479</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS092091</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2022 Sep;18(9):513-514</RefSource><PMID Version="1">35821306</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2023 Oct 3;146(10):e80-e82</RefSource><PMID Version="1">37186590</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2023 Oct 3;146(10):e77-e79</RefSource><PMID Version="1">37202873</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="N">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057210" MajorTopicYN="N">Delayed Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068079" MajorTopicYN="Y">Motor Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">phenoconversion</Keyword><Keyword MajorTopicYN="N">pre-symptomatic</Keyword><Keyword MajorTopicYN="N">prodromal disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>20</Day><Hour>12</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35594156</ArticleId><ArticleId IdType="pmc">PMC9586537</ArticleId><ArticleId IdType="doi">10.1093/brain/awac185</ArticleId><ArticleId IdType="pii">6589620</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et al. . Amyotrophic lateral sclerosis&#x2014;Frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:153&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: A candidate biomarker of pre-symptomatic ALS and phenoconversion. Ann Neurol. 2018;84:130&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Lombardi V, et al. . Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:538&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6768722</ArticleId><ArticleId IdType="pubmed">31432691</ArticleId></ArticleIdList></Reference><Reference><Citation>Swash M, Ingram D. Preclinical and subclinical events in motor neuron disease. J Neurol Neurosurg Psychiatry. 1988;51:165&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1031524</ArticleId><ArticleId IdType="pubmed">3346681</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Swash M. The onset of ALS? Clin Neurophysiol. 2010;121:1709&#x2013;1710.</Citation><ArticleIdList><ArticleId IdType="pubmed">20674486</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Turner MR, Wuu J. Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:303&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6613999</ArticleId><ArticleId IdType="pubmed">30892087</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, McHutchison C, et al. . Preventing amyotrophic lateral sclerosis: Insights from pre-symptomatic neurodegenerative diseases. Brain. 2022;145:27&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8967095</ArticleId><ArticleId IdType="pubmed">34677606</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J. Presymptomatic studies in ALS: Rationale, challenges, and approach. Neurology. 2012;79:1732&#x2013;1739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3468777</ArticleId><ArticleId IdType="pubmed">23071166</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Zhang L, Wang L, et al. . Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020;95:e59&#x2013;e69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7371380</ArticleId><ArticleId IdType="pubmed">32385188</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen P, Forsgren L, Binzer M, et al. . Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutations. Brain. 1996;119:1153&#x2013;1172.</Citation><ArticleIdList><ArticleId IdType="pubmed">8813280</ArticleId></ArticleIdList></Reference><Reference><Citation>Lule DE, Muller HP, Finsel J, et al. . Deficits in verbal fluency in presymptomatic C9orf72 mutation gene carriers-a developmental disorder. J Neurol Neurosurg Psychiatry. 2020;91:1195&#x2013;1200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7569387</ArticleId><ArticleId IdType="pubmed">32855285</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopate G, Baloh RH, Al-Lozi MT, et al. . Familial ALS with extreme phenotypic variability due to the I113T SOD1 mutation. Amyotroph Lateral Scler. 2010;11:232&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">20184521</ArticleId></ArticleIdList></Reference><Reference><Citation>Juneja T, Pericak-Vance MA, Laing NG, Dave S, Siddique T. Prognosis in familial amyotrophic lateral sclerosis: Progression and survival in patients with glu100gly and ala4val mutations in Cu, Zn superoxide dismutase. Neurology. 1997;48:55&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">9008494</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, McKenna-Yasek D, Sapp PE, et al. . Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann Neurol. 1997;41:210&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">9029070</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J. The challenge of early therapeutic intervention in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:5.</Citation></Reference><Reference><Citation>Cellura E, Spataro R, Taiello AC, La Bella V. Factors affecting the diagnostic delay in amyotrophic lateral sclerosis. Clin Neurol Neurosurg. 2012;114:550&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">22169158</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraemer M, Buerger M, Berlit P. Diagnostic problems and delay of diagnosis in amyotrophic lateral sclerosis. Cli Neurol Neurosurg. 2010;112:103&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">19931253</ArticleId></ArticleIdList></Reference><Reference><Citation>Nzwalo H, de Abreu D, Swash M, Pinto S, de Carvalho M. Delayed diagnosis in ALS: The problem continues. J Neurol sci. 2014;343:173&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">24972820</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Lee A, et al. . Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:453&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4433003</ArticleId><ArticleId IdType="pubmed">24981792</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoccolella S, Beghi E, Palagano G, et al. . Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: A population-based study. J Neurol Sci. 2006;250:45&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">16920152</ArticleId></ArticleIdList></Reference><Reference><Citation>
Britannica Encyclopaedia (Editors of) . &#x2018;Sorites problem&#x2019;. Encyclopedia Britannica 2011. Accessed 18 December 2021. https://www.britannica.com/topic/sorites-problem</Citation></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, et al. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Pre-Symptomatic SOD1 Variant Carriers: the ATLAS Study. Neurotherapeutics. Published online 18 May 2022. doi:10.1007/s1311-022-01237-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9587202</ArticleId><ArticleId IdType="pubmed">35585374</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>